Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2015-11-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 191
- Registration Number
- NCT00802841
- Locations
- 🇻🇪
Novartis Investigative Site, Maracaibo, Estado Zulia, Venezuela
An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2020-09-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 34
- Registration Number
- NCT00799266
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
Confirmatory Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT00794157
- Locations
- 🇯🇵
Novartis Investigative site, Tokyo, Japan
🇨🇳Novartis Investigator Site, Taipei, Taiwan
🇨🇳Novartis Investigative Site, Taipei, Taiwan
Efficacy and Safety of Indacaterol in Adults (40 Years and Above) With Chronic Obstructive Pulmonary Disease (COPD)
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2008-11-18
- Last Posted Date
- 2011-08-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 563
- Registration Number
- NCT00792805
- Locations
- 🇨🇳
Novartis Investigator Site, Fuzhou, China
🇮🇳Novartis Investigative Site, Trivandrum, India
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
- Conditions
- Neoplasms, Breast
- Interventions
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2018-02-28
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT00790816
- Locations
- 🇪🇸
Novartis Investigative Site, Hospitalet de Llobregat (Barcelona), Spain
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 742
- Registration Number
- NCT00790036
- Locations
- 🇺🇸
Medical University of South Carolina -Hollings Cancer Center MUSC/HCC (2), Charleston, South Carolina, United States
🇺🇸Ironwood Cancer and Research Centers SC, Chandler, Arizona, United States
🇺🇸Levine Cancer Institute Oncology, Charlotte, North Carolina, United States
Phase II Study of TKI258 in Advanced Urothelial Carcinoma
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 44
- Registration Number
- NCT00790426
- Locations
- 🇺🇸
USC/Kenneth Norris Comprehensive Cancer Center Regulatory Contact 3, Los Angeles, California, United States
🇺🇸University Chicago Hospital CTKI258A2201, Chicago, Illinois, United States
🇺🇸Duke University Medical Center Dept.ofDukeUniversityMedCtr(2), Durham, North Carolina, United States
Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)
- Conditions
- Tuberous SclerosisSubependymal Giant Cell Astrocytoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 117
- Registration Number
- NCT00789828
- Locations
- 🇬🇧
Novartis Investigative Site, Bristol, United Kingdom
🇺🇸Minnesota Epilepsy Group - PA, St. Paul, Minnesota, United States
🇺🇸Children's Hospital Oakland Hematology/Oncology Dept, Oakland, California, United States
Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
- Conditions
- Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC)
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT00790400
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Minnesota Epilepsy Group, St. Paul, Minnesota, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- HER-2 Positive Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00788931
- Locations
- 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands